- Dr.
Almenoff brings more than 25 years of drug development and
leadership
experience to the Actinium Board of Directors
- Dr.
Almenoff to join Actinium's Nominating and Corporate Governance
Committee
NEW
YORK, Nov. 4, 2024 /PRNewswire/ -- Actinium
Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the
Company), a leader in the development of Antibody Radiation
Conjugates (ARCs) and other targeted radiotherapies, today
announced the appointment of June
Almenoff, M.D., Ph.D. to its Board of Directors. Dr.
Almenoff is an accomplished biopharma executive with over 25 years
of senior leadership and drug development experience. She currently
serves as a Board Director and advisor to numerous biopharma
companies.
Andes Seth, Actinium's Chairman and CEO, stated, "Through her
career, June has amassed significant experience in translational
research, drug development and business development that has
resulted in multiple approved products and value creation. Her
experience will be invaluable to Actinium and we are delighted to
add Dr. Almenoff to the Actinium Board."
Dr. Almenoff served as President and Chief Medical Officer of
Furiex Pharmaceuticals, which was acquired by Actavis plc (now
AbbVie) for $1.2B. Furiex developed
eluxadoline (Viberzi®), which was approved both in the United States and Europe. She also served as Chief Medical
Officer of RedHill Biopharma Ltd (Nasdaq: RDHL) leading a team
whose work led to the recognition of Talicia® as a first-line
therapy for H. pylori. Earlier in her career, Dr.
Almenoff was at GlaxoSmithKline (GSK) for 12 years, where she held
various positions of increasing responsibility. She was a Vice
President in the Clinical Safety Organization, chaired a PhRMA-FDA
working group, and worked in the area of scientific licensing. She
also led the development of pioneering data analytics systems,
which have been widely adopted by industry and regulators to
minimize clinical risk for pharmaceutical products.
Dr. Almenoff has strong expertise in translational medicine,
clinical development, commercial strategy, and business development
across many therapeutic areas, and has led or contributed to
numerous regulatory submissions, product approvals and launches.
She is a member of the investment advisory board of the Harrington
Discovery Institute, a director on the board of Avalo Therapeutics,
Inc. (Nasdaq: AVTX) and Tenax Therapeutics (Nasdaq: TENX).
Dr. Almenoff added, "Targeted radiotherapy has become an
important treatment option for patients in multiple oncology
indications, which I believe will only continue to expand. I am
impressed by Actinium's innovative R&D, clinical development
experience and capabilities, as well as its proprietary
Actinium-225 manufacturing technology. Collectively, Actinium has
the vision and components to become a leading fully integrated
specialty radiopharmaceutical company. I am excited to join the
Actinium Board and look forward to working to help the company
realize its vision and create value for patients and shareholders
alike."
Dr. Almenoff received her B.A. cum laude from Smith College and graduated with Alpha Omega Alpha honors from the M.D.-Ph.D.
program at the Icahn (Mt. Sinai)
School of Medicine. She completed post-graduate medical training at
Stanford University Medical Center and
served on the faculty of Duke
University School of Medicine. She is an adjunct professor
at Duke, a Fellow of the American
College of Physicians (FACP) and has authored over 70
publications.
About Actinium Pharmaceuticals, Inc.
Actinium develops Antibody Radiation Conjugates ("ARCs") and
other targeted radiotherapies intended to meaningfully improve
outcomes for people who have failed existing oncology therapies.
Iomab-B is an induction and conditioning agent prior to bone marrow
transplant in patients with relapsed and refractory acute myeloid
leukemia ("r/r AML"), which Actinium is seeking a potential
strategic partner for in the U.S. The company continues to advance
its development for product candidate Actimab-A, a therapeutic
agent that has demonstrated potential activity in r/r AML patients.
In addition, Actinium is engaged with the National Cancer Institute
("NCI") under the Cooperative Research and Development Agreement
("CRADA") for development of Actimab-A in AML and other myeloid
malignancies. Iomab-ACT, Actinium's next generation conditioning
candidate, is being developed with the goal of improving patient
access and outcomes for potentially curative cell and gene
therapies. In addition, the company's R&D efforts are primarily
focused on advancing several preclinical programs for solid tumor
indications. Actinium holds more than 235 patents and patent
applications including several patents related to the manufacture
of the isotope Ac-225 in a cyclotron.
For more information, please
visit: https://www.actiniumpharma.com/
Forward-Looking Statements
This press release may contain projections or other
"forward-looking statements" within the meaning of the
"safe-harbor" provisions of the private securities litigation
reform act of 1995 regarding future events or the future financial
performance of the Company which the Company undertakes no
obligation to update. These statements are based on management's
current expectations and are subject to risks and uncertainties
that may cause actual results to differ materially from the
anticipated or estimated future results, including the risks and
uncertainties associated with preliminary study results varying
from final results, estimates of potential markets for drugs under
development, clinical trials, actions by the FDA and other
governmental agencies, regulatory clearances, responses to
regulatory matters, the market demand for and acceptance of
Actinium's products and services, performance of clinical research
organizations and other risks detailed from time to time in
Actinium's filings with the Securities and Exchange Commission (the
"SEC"), including without limitation its most recent annual report
on form 10-K, subsequent quarterly reports on Forms 10-Q and Forms
8-K, each as amended and supplemented from time to time.
Investors:
investorrelations@actiniumpharma.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/actinium-pharmaceuticals-appoints-accomplished-biopharma-industry-executive-june-almenoff-md-phd-to-its-board-of-directors-302295025.html
SOURCE Actinium Pharmaceuticals, Inc.